Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

OXY · Q1 20262026-05-06TROW · Q2 20252025-08-01RGS · Q2 20262026-02-05VNCE · Q3 20252025-12-09NDSN · Q3 20252025-08-21NABL · Q1 20262026-05-07TKNO · Q1 20262026-05-06SGI · Q1 20262026-05-07OSUR · Q3 20252025-11-05DT · Q1 20262025-08-06MOS · Q2 20252025-08-06BBWI · Q4 20252026-03-04PPL · Q4 20252026-02-20

Nearby prompts. All 1,000 Earnings calls prompts

PromptTKNO· Q1 2026 · call on2026-05-06· transcript 25,539 characters
Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>
System prompt · identical for every setup
You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.
Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Models
4 of 4 columns · click a model to add or remove it

Ours

10 facts · valid JSON
  1. Total revenue for Q1 2026 grew 13% year-over-year, reaching a level of over $11 million for the first time in nearly three years.
  2. Clinical Solutions revenue surged 85% to $2.1 million, driven primarily by an increased customer count rather than just lumpy large orders.
  3. Lab Essentials revenue grew only 3% to $8.4 million, as higher average revenue per customer was partially offset by a decrease in total customer numbers.
  4. Gross margin improved to 34.2% in Q1 2026, up from 30.7% in the prior year period, driven by revenue leverage.
  5. Adjusted EBITDA loss narrowed to negative $2.0 million in Q1 2026 compared to negative $2.5 million in the same period the previous year.
  6. The company expects to achieve Adjusted EBITDA profitability when annualized revenue reaches the $52 million to $57 million range.
  7. Full-year 2026 revenue guidance remains at $42 million to $44 million, representing approximately 6% growth at the midpoint despite Q1 acceleration signals.
  8. The company projects approximately 20% revenue growth for 2027, driven by biotech funding recovery, clinical pipeline advancements, and ramping commercial investments.
  9. Operational efficiency initiatives include tripling single batch production sizes and converting 90% of paper batch records to digital to reduce unit costs.
  10. The company currently supports approximately 70 therapies in development pipelines, five of which are in Phase II or III nearing commercial completion.
1,527 characters370 tokens

Aux 2015

Invalid JSONshown as written

Based on the transcript, here are the 10 most investor-relevant facts extracted from the Alpha Teknova, Inc. earnings call:

  1. Revenue Growth: The company reported revenue growth of 13% in the first quarter, exceeding expectations.
  2. Clinical Solutions Growth: Revenue from Clinical Solutions products increased 85% compared to the same period last year, driven by an increase in customer count and higher average revenue per customer.
  3. Gross Margin: Gross margin was 34.2% in the first quarter, up from 30.7% in the same period last year.
  4. Operating Expenses: Operating expenses were $8.1 million in the first quarter, up from $8.0 million in the same period last year.
  5. Adjusted EBITDA: Adjusted EBITDA was negative $2.0 million in the first quarter, compared to negative $2.5 million in the same period last year.
  6. Cash Usage: The company reported negative free cash outflow of $3.6 million in the first quarter, compared to negative $4.3 million in the same period last year.
  7. Commercial Investment: The company increased its commercial spend to $2 million in the first quarter, split between marketing and sales.
  8. Lab Essentials Growth: Lab Essentials revenue increased 3% compared to the same period last year, driven by higher average revenue per customer.
  9. Clinical Solutions Growth: Clinical Solutions revenue increased 85% compared to the same period last year, driven by an increase in customer count and higher average revenue per customer.
  10. Revenue Outlook: The company expects revenue growth of 6% to 8% in 2026, with a midpoint of 6% growth.
1,615 charactersfirst of 2 attempts381 tokens

PiT-FT 2015

Invalid JSONshown as written
<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

4,099 charactersfirst of 2 attempts2,048 tokens

ChronoGPT 2015

Invalid JSONshown as written

### Outgoing Events:

-

-

-

-

-

-

-
50 charactersfirst of 2 attempts31 tokens